XSHE
300181
Market cap1.36bUSD
Oct 09, Last price
13.25CNY
1D
0.99%
1Q
-1.56%
Jan 2017
45.13%
IPO
226.74%
Name
Zhejiang Jolly Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Jolly Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, manufacturing, and global distribution of traditional Chinese medicinal products. The company's diverse portfolio includes the Wuling capsule, prescribed for conditions such as insomnia, amnesia, heart palpitations, general fatigue, weakness in the lower back and legs, and tinnitus. This capsule also addresses energy deficiency and a weak pulse often linked to an imbalance of the heart and kidneys, or neurasthenia. Additionally, they produce the Lingze tablet, which targets frequent or painful urination, weak or continuous urine flow, and lower back and knee soreness, especially when these symptoms are associated with benign prostatic hyperplasia, kidney insufficiency, or blood stasis. Another offering, the Bailing tablet, serves as an adjunctive treatment for coughs, asthma, back pain, and chronic bronchitis stemming from lung and kidney deficiencies. The firm also markets Linglianhua particles, used to manage symptoms including excessive sweating, sleep disturbances, irritability, heart flutters, vivid dreams, dizziness with tinnitus, lower back and leg weakness, dry stools, an unusual tongue appearance, and a feeble pulse, often seen in perimenopausal syndrome or heart and kidney disharmony. Beyond these traditional Chinese medicine formulations, Zhejiang Jolly Pharmaceutical provides a range of injectable pharmaceuticals, such as azithromycin, clindamycin phosphate, doxapram, pefloxacin mesylate, adenosine cyclophosphate, and sodium nitroprusside. The company further supplies raw medicinal ingredients, including cordyceps cephalosporium, fermented cordyceps, and Wuling powders. Expanding its reach into healthcare services, Zhejiang Jolly Pharmaceutical Co., Ltd. invests in and participates with Deqing No.3 People's Hospital. Established in 2000 and based in Huzhou, China, the entity now known as Zhejiang Jolly Pharmaceutical Co., Ltd. adopted this name in 1998, evolving from its earlier designation, Zhejiang Jolly Pharmaceutical Health Products Co., LTD.
Key people
Youqiang Yu
Chairman of the Board · since 2003
Tao Wang
General Manager, Director · since 2024
Jian Chen
Deputy General Manager · since 2008
Aihua Ma
Deputy General Manager · since 2022
Xiaoguo Peng
Deputy General Manager · since 2018
Yuehong Shen
Deputy General Manager, Staff Elected Director · since 2025
Xin Tan
Deputy General Manager · since 2023
Li Ye
Chief Financial Officer, Deputy General Manager · since 2022
Ying Wu
Secretary of the Board · since 2024
Guofu Feng
Executive Deputy General Manager, Director · since 2024
Jianjun Wang
Director · since 2018
Director · since 2014
Ping Wang
Independent Director · since 2021
Jie Yao
Independent Director · since 2024
Independent Director · since 2021
Headquarters & legal address
浙江省德清县阜溪街道志远北路388号
湖州市, ZJ 310000
CN
湖州市, ZJ 310000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||